Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Bortezomib: 3 deaths following intrathecal injection.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):214. No abstract available.

PMID:
23016258
2.

Fatalities resulting from accidental intrathecal administration of bortezomib: strategies for prevention.

Gilbar PJ, Seger AC.

J Clin Oncol. 2012 Sep 20;30(27):3427-8. doi: 10.1200/JCO.2012.44.5866. Epub 2012 Jul 30. No abstract available.

3.

Persistent supravenous eruption induced by intravenous bortezomib therapy.

Mataix J, Betlloch I, Palmero F, Romero A.

Br J Dermatol. 2008 Apr;158(4):863-4. doi: 10.1111/j.1365-2133.2008.08438.x. Epub 2008 Feb 16. No abstract available.

PMID:
18284402
4.

Subcutaneous bortezomib: a step towards optimised drug use.

Mateos MV.

Lancet Oncol. 2011 May;12(5):410-1. doi: 10.1016/S1470-2045(11)70098-5. Epub 2011 Apr 18. No abstract available.

PMID:
21507716
5.

Accidental intrathecal administration of bortezomib: preventing fatalities.

Gilbar PJ, Seger AC.

Asia Pac J Clin Oncol. 2013 Sep;9(3):290-1. doi: 10.1111/ajco.12020. Epub 2012 Nov 26. No abstract available.

PMID:
23176407
6.

Deaths reported from the accidental intrathecal administration of bortezomib.

Gilbar P, Seger AC.

J Oncol Pharm Pract. 2012 Sep;18(3):377-8. doi: 10.1177/1078155212453752. Epub 2012 Jul 16.

PMID:
22801956
7.

Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

Kamimura T, Miyamoto T, Takashima S, Yokota N, Chong Y, Ito Y, Akashi K.

Int J Hematol. 2012 Oct;96(4):525-7. doi: 10.1007/s12185-012-1167-x. Epub 2012 Sep 8. No abstract available.

PMID:
22961216
8.

[Effect of Velcade combined with Dexamethasone on multiple myeloma].

He Q, Zhao X, He Y, Tan D.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Aug;35(8):864-7. doi: 10.3969/j.issn.1672-7347.2010.08.015. Chinese.

9.

Enhancing care and managing side effects in patients receiving bortezomib.

Colson K.

Clin Adv Hematol Oncol. 2006 May;4(5):6-7; discussion 8; suppl 13. No abstract available.

PMID:
16832860
10.

An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.

Ohgiya D, Tsuchiya T, Suyama T, Watanabe S, Numata H, Tsuboi K, Sasao T.

Acta Haematol. 2015;133(1):29-30. doi: 10.1159/000362587. Epub 2014 Jul 1. No abstract available.

PMID:
24993672
11.

Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.

Aguayo-Leiva I, Vano-Galvan S, Carrillo-Gijon R, JaƩn-Olasolo P.

J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1363-4. doi: 10.1111/j.1468-3083.2010.03643.x. No abstract available.

PMID:
20337821
12.

Bortezomib plus melphalan and prednisone for multiple myeloma.

Tsubokura M, Kami M, Komatsu T.

N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. No abstract available.

PMID:
19090031
13.

Bortezomib-related diffuse alveolar hemorrhage.

Wirk B.

J Clin Oncol. 2012 Dec 20;30(36):e379-81. doi: 10.1200/JCO.2012.43.6519. Epub 2012 Nov 13. No abstract available.

14.

Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years.

Parrish C, Cromack J, Feyler S, Ashcroft J, Owen R, Cook G.

Br J Haematol. 2011 Apr;153(2):273-5. doi: 10.1111/j.1365-2141.2010.08565.x. Epub 2011 Jan 31. No abstract available.

PMID:
21275974
15.

[Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].

Fukushima T, Iwao H, Nakajima A, Miki M, Sakai T, Sawaki T, Tanaka M, Masaki Y, Hirose Y, Umehara H.

Gan To Kagaku Ryoho. 2009 Aug;36(8):1387-9. Japanese.

PMID:
19692786
16.

Bortezomib plus melphalan and prednisone for multiple myeloma.

Avvisati G.

N Engl J Med. 2008 Dec 11;359(24):2613; author reply 2613-4. No abstract available.

PMID:
19090032
17.

Cutaneous lesion induced by a subcutaneous administration of bortezomib.

Obeid KM, Ferrara R, Sharma M.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):284-6. doi: 10.1016/j.clml.2012.05.002. Epub 2012 May 24. No abstract available.

PMID:
22633164
18.

The safety and efficacy of bortezomib in relapsed multiple myeloma.

Jagannath S.

Clin Adv Hematol Oncol. 2006 May;4(5):2-3; discussion 8; suppl 13. No abstract available.

PMID:
16830423
19.

Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.

Yokose N, Hirakawa T, Inokuchi K.

Leuk Res. 2009 Aug;33(8):e106. doi: 10.1016/j.leukres.2009.02.021. Epub 2009 Mar 13. No abstract available.

PMID:
19285724
20.

The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.

Tong Y, Qian J, Li Y, Meng H, Jin J.

Am J Hematol. 2007 May;82(5):403-4.

Items per page

Supplemental Content

Write to the Help Desk